These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 32682351)
1. Clinical characteristics of hypertrophic cardiomyopathy in children: An 8-year single center experience. Tunca Sahin G; Ozgur S; Kafali HC; Sevinc Sengul F; Haydin S; Guzeltas A; Ergul Y Pediatr Int; 2021 Jan; 63(1):37-45. PubMed ID: 32682351 [TBL] [Abstract][Full Text] [Related]
2. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286 [TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study. Balaji S; DiLorenzo MP; Fish FA; Etheridge SP; Aziz PF; Russell MW; Tisma S; Pflaumer A; Sreeram N; Kubus P; Law IH; Kantoch MJ; Kertesz NJ; Strieper M; Erickson CC; Moore JP; Nakano SJ; Singh HR; Chang P; Cohen M; Fournier A; Ilina MV; Smith RT; Zimmerman F; Horndasch M; Li W; Batra A; Liberman L; Hamilton R; Janson CM; Sanatani S; Zeltser I; McDaniel G; Blaufox AD; Garnreiter JM; Katcoff H; Shah M Heart Rhythm; 2019 Oct; 16(10):1462-1467. PubMed ID: 31026510 [TBL] [Abstract][Full Text] [Related]
5. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience. Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403 [TBL] [Abstract][Full Text] [Related]
6. Management of hypertrophic cardiomyopathy in children. Seggewiss H; Rigopoulos A Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624 [TBL] [Abstract][Full Text] [Related]
13. Clinical profile and outcomes of pediatric hypertrophic cardiomyopathy in a South Indian tertiary care cardiac center: a three decade experience. Mukhtar G; Sasidharan B; Krishnamoorthy KM; Kurup HKN; Gopalakrishnan A; SasiKumar D; P SS; Valaparambil AK; Sivasubramonian S; Sivadasanpillai H BMC Pediatr; 2023 Sep; 23(1):446. PubMed ID: 37679699 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505 [TBL] [Abstract][Full Text] [Related]
15. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044 [TBL] [Abstract][Full Text] [Related]
16. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM]. Maron BJ; Spirito P Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):297-302. PubMed ID: 19791462 [TBL] [Abstract][Full Text] [Related]
17. [Sudden cardiac death in familial hypertrophic cardiomyopathy. Identification of high-risk patients]. Pellnitz C; Geier C; Perrot A; Dietz R; Osterziel KJ; Haverkamp W Dtsch Med Wochenschr; 2005 May; 130(18):1150-4. PubMed ID: 15856398 [TBL] [Abstract][Full Text] [Related]
18. Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario. Weissler-Snir A; Allan K; Cunningham K; Connelly KA; Lee DS; Spears DA; Rakowski H; Dorian P Circulation; 2019 Nov; 140(21):1706-1716. PubMed ID: 31630535 [TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692 [TBL] [Abstract][Full Text] [Related]
20. Mid-term outcomes of biventricular obstruction and left ventricular outflow tract obstruction after surgery correction in child and adolescent patients with hypertrophic cardiomyopathy. Zhai S; Xu H; Fan C; Yang Y; Hang F; Guo X; Wang H; Duan F; Yan J PLoS One; 2018; 13(2):e0192218. PubMed ID: 29408870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]